Clinical Trials (PDQ®)
Phase II Study of Suberoylanilide Hydroxamic Acid in Patients With Progressive, Persistent, or Recurrent Stage IB-IV Cutaneous T-Cell Lymphoma
|Phase II||Treatment||Closed||18 and over||NCI, Pharmaceutical / Industry||UCLA-0412112-01|
MERCK-CL-01-0303 (2), NCT00091559, MERCK-001-02
Eligibility criteria include the following:
- At least 18 years old
- For more information about the eligibility criteria for this trial, refer to the Health Professional version.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Patients will receive suberoylanilide hydroxamic acid by mouth once a day. Treatment may continue for as long as benefit is shown.
Patients will be evaluated within 4 weeks and once a year thereafter.
For more details about this trial, refer to the Health Professional version of the trial summary.
If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.
Trial Lead Organizations
Jonsson Comprehensive Cancer Center at UCLA
|Lauren Pinter-Brown, MD, Protocol chair|
|Official Title||Phase IIB Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-Cell Lymphoma|
|Registered in ClinicalTrials.gov||NCT00091559|
|Date Submitted to PDQ||2005-05-11|
|Information Last Verified||2007-07-30|
|NCI Grant/Contract Number||P30-CA16042|